명의 월스트리트 애널리스트에 따르면, Vycor Medical Inc의 매출 추정치는 $에서 $까지입니다.
Vycor Medical Inc의 수익 품질 점수는 얼마인가요?
Vycor Medical Inc의 수익 품질 점수는 B+/51.568443입니다. 이 점수는 수익성, 성장, 현금 창출 및 자본 배분, 레버리지의 네 가지 차원을 기반으로 합니다.
Vycor Medical Inc는 언제 수익을 보고하나요?
Vycor Medical Inc의 다음 수익 보고서는 2026-02-12에 발표될 예정입니다.
Vycor Medical Inc의 예상 수익은 얼마인가요?
월스트리트 애널리스트에 따르면 Vycor Medical Inc의 예상 수익은 $입니다.
Vycor Medical Inc은 수익 기대치를 충족했나요?
Vycor Medical Inc의 최근 수익은 $로, 기대치를 .
주요 통계
이전 종가
$0.09
시가
$0.0979
일일 범위
$0.0689 - $0.0979
52주 범위
$0.051 - $0.5
거래량
3.0K
평균 거래량
6.8K
배당수익률
--
EPS(TTM)
-0.00
시가총액
$3.0M
VYCO란 무엇인가요?
Vycor Medical, Inc. engages in the provision of innovative surgical and therapeutic solutions to the medical community. The company is headquartered in Boca Raton, Florida and currently employs 7 full-time employees. The company went IPO on 2009-03-31. The firm designs, develops and markets neurological medical devices and therapies. The firm operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage, such as that caused by a stroke. Vycor Medical’s ViewSite Brain Access System (VBAS) is a next-generation retraction and access system. VBAS is a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system is used in over 300 hospitals in the United States and in numerous countries internationally. NovaVision products include Visual Restoration Therapy (VRT) and NeuroEyeCoach.